Curis to Present at Upcoming Healthcare Conference in July

Rhea-AI Summary

Curis, a biotechnology company listed on NASDAQ under the ticker CRIS, announced that its President and CEO, James Dentzer, will present at the Jones Healthcare Seaside Summit 2024. The presentation is scheduled for July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET). Curis focuses on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor. A live webcast and an archived replay of the presentation will be accessible through the Events & Presentations section of Curis's website.

LEXINGTON, Mass., July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET). A live webcast and archived replay will be available and can be accessed here or on the Events & Presentations section of Curis's website.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conference-in-july-302192752.html

SOURCE Curis, Inc.

FAQ

When will Curis present at the Jones Healthcare Seaside Summit 2024?

Curis will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET).

Who will represent Curis at the Jones Healthcare Seaside Summit 2024?

James Dentzer, the President and CEO of Curis, will represent the company at the Jones Healthcare Seaside Summit 2024.

What is emavusertib (CA-4948) developed by Curis?

Emavusertib (CA-4948) is an orally available, small molecule IRAK4 inhibitor developed by Curis.

Where can I access the webcast of Curis's presentation at the Jones Healthcare Seaside Summit 2024?

A live webcast and archived replay of Curis's presentation will be available on the Events & Presentations section of Curis's website.

What is the stock symbol for Curis?

The stock symbol for Curis is CRIS.